Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR142 | Q7Z601 | 7/20 | 0.57 |
| ▸ | BCL2 | P10415 | 2/20 | 0.53 |
| ▸ | CTSS | P25774 | 4/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2686177 | 1.00 | GPR142 (0.57) | GPR142BCL2CTSSCTSKCTSB | |
| SCHEMBL13258455 | 0.91 | GPR142 (0.53) | GPR142BCL2CTSSCTSKCTSB | |
| SCHEMBL6032932 | 0.86 | CTSS (0.54) | GPR142BCL2CTSSCTSKCTSB | |
| SCHEMBL2686204 | 0.80 | GPR142 (0.62) | GPR142LRRK2AKT1 | |
| SCHEMBL2686199 | 0.80 | GPR142 (0.62) | GPR142LRRK2AKT1 | |
| SCHEMBL2686800 | 0.76 | GPR142 (0.61) | GPR142BCL2CTSSCTSKCTSB | |
| SCHEMBL13258365 | 0.76 | GPR142 (0.61) | GPR142CTSSCTSKCTSBCTSL | |
| SCHEMBL2686802 | 0.76 | GPR142 (0.61) | GPR142BCL2CTSSCTSKCTSB | |
| SCHEMBL27515453 | 0.76 | CTSS (0.59) | CTSSCTSKCTSBCTSLHDAC8 | |
| SCHEMBL13258413 | 0.76 | GPR142 (0.52) | GPR142BCL2CTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785468-B2 | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions | AMGEN INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | AMGEN INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | IAPP, INSR, AMY2A | GPR142 2779/4885BCL2 2006/4885CTSS 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.